Trial
NCT02779153
Acthar SLE (Systemic Lupus Erythematosus)
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
NYU Langone Health
Collaborators
Mallinckrodt
Condition
Systemic Lupus Erythematosus (SLE)
Intervention
Acthar low dose (40 U)
Why stopped
closed in agreement of the sponsor and institution due to lack of patient accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-13